Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS

Inclusion Criteria:

   - Any patient with suspected brain tumor diagnosed by MRI

   - Patients undergoing neuro-imaging evaluation by the neurosurgical service for other
   indications (e.g. vascular malformations, traumatic brain injury, ischemic and
   hemorrhagic stroke, CNS infections, and neuro-degenerative diseases)

Exclusion Criteria:

   - Informed consent cannot be obtained either from the patient or legal representative

   - Severe coexisting or terminal systemic disease that limits life expectancy or that may
   interfere with the conduct of the study

   - Contraindication to MRI (metal implants)

   - Hemosiderosis/hemochromatosis

   - Need for sedation or anesthesia (claustrophobia) that will not otherwise be undertaken
   as part of routine clinical care (e.g. routine MRI under sedation already planned)

   - Known hypersensitivity to Feraheme (ferumoxytol) or any of its components

   - Iron overload from any cause (not just hemosiderosis or hemochromatosis), even if
   secondary to frequent blood transfusions, severe chronic hemolysis, excess dietary or
   parenteral iron, or any other etiology